Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Infectious Disease · Genitourinary Tuberculosis

Medical Treatment Strategy for Genitourinary TB

At a Glance

Genitourinary TB is usually treated with several TB medicines at first, followed by fewer medicines, for a total of about six months. Close monitoring, adherence support, interaction checks, and follow-up with a urologist help protect kidney function.

Genitourinary tuberculosis (GUTB) is a serious condition that requires dedicated treatment. Because TB bacteria are “tough” and grow slowly, treatment requires a combination of several anti-TB medicines taken over a long period [1][2].

While the medicine treats the active infection, it cannot always reverse existing scars or blockages. Therefore, your medical treatment is often paired with close monitoring by a urologist to protect your kidney function [3][4].

The Medical Regimen

A common regimen for drug-susceptible GU TB is a two-phase treatment plan [5][6]. However, the actual drugs, dosing schedule, duration, and need for expert consultation depend on susceptibility, HIV and antiretroviral therapy, pregnancy, kidney or liver disease, drug interactions, and local TB-program guidance.

Phase 1: The Intensive Phase (Often 2 Months)

For the first phase, patients typically take four different medications daily [5][1]:

  1. Isoniazid
  2. Rifampin
  3. Pyrazinamide
  4. Ethambutol

Phase 2: The Continuation Phase (Often 4 Months)

The continuation phase is generally planned from the outset and modified if cultures, susceptibility results, toxicity, or clinical response require it. It usually drops to two drugs [5][1]:

  1. Isoniazid
  2. Rifampin

Note: In complex cases involving deep kidney abscesses, HIV coinfection, or slow response, your doctor may extend the treatment duration beyond six months [2].

Supporting Your Success: Adherence and DOT

Missed doses reduce treatment effectiveness, but resistance can also be pre-existing or related to inadequate drug exposure and interactions. Do not double doses. Contact the TB team promptly after missed doses or vomiting [6][7].

  • Directly Observed Therapy (DOT): Many programs offer individualized adherence support where a trained health worker or designated support person helps you manage any side effects [6].
  • Modern Options: Some programs offer “video DOT,” providing flexibility while maintaining safety [8].

Managing Side Effects and Monitoring

These medications require baseline and symptom/risk-based monitoring according to the TB program [9].

Contact the TB team URGENTLY for:

  • New visual changes (blurry sight or trouble telling red from green) [9][10].
  • Jaundice (yellowing of skin/eyes), dark urine, severe or persistent nausea/vomiting, abdominal pain, or marked loss of appetite (signs of hepatotoxicity) [9].
  • Unusual bleeding, rash, fever, or severe weakness [9].

Do not tell patients to stop or continue drugs on your own; provide the clinician-directed plan.

Medication Common & Notable Side Effects Baseline & Risk-Based Monitoring
Rifampin Orange discoloration of urine, sweat, and tears (harmless); nausea; reduced effectiveness of other drugs [11][9]. Baseline blood counts [9].
Isoniazid Liver inflammation; tingling or numbness in hands/feet (peripheral neuropathy) [9]. Liver function tests; Vitamin B6 (pyridoxine) supplements prescribed based on risk [9].
Pyrazinamide Joint pain; high uric acid levels; liver stress [12][9]. Liver function tests; uric acid checks [9].
Ethambutol Changes in vision [9][10]. Baseline vision tests [9].

Important Warning: Hepatotoxicity Plan

Isoniazid, rifampin, and pyrazinamide can all cause liver injury. Patients need explicit instructions to contact the TB team urgently for jaundice, dark urine, severe or persistent nausea/vomiting, abdominal pain, or marked loss of appetite.

Drug Interactions

Rifampin causes your liver to process other medications much faster than usual [13][14].

  • Birth Control and Pregnancy: Rifampin can reduce the effectiveness of many hormonal contraceptives. The appropriate alternative or backup depends on the method; depot medroxyprogesterone and nonhormonal options may be considered, and pregnancy planning requires TB-specialist and obstetric advice [13].
  • Other Drugs: Interactions are common with blood thinners (anticoagulants), antiretrovirals, transplant drugs, methadone, seizure medicines, and other narrow-therapeutic-index drugs [15][16]. Always provide your doctor with a complete list.

Long-Term Outcomes

For most patients, the regimen is highly effective at treating the active infection [17][18]. However, clearing the bacteria is only the first step. You will need long-term follow-up to ensure that any scarring in the ureters or bladder doesn’t lead to new blockages or permanent kidney damage [4][18].

Common questions in this guide

Which medicines are usually used for genitourinary TB?
For drug-susceptible genitourinary TB, treatment often starts with isoniazid, rifampin, pyrazinamide, and ethambutol. After the intensive phase, treatment commonly continues with isoniazid and rifampin, but the exact drugs and schedule depend on susceptibility results, other health conditions, and clinician guidance.
How many months will I need treatment for genitourinary TB?
A common plan lasts about six months, with roughly two months of four medicines followed by about four months of two medicines. Treatment can be longer when there are deep kidney abscesses, HIV, a slow response, drug resistance, toxicity, or other clinical concerns.
What should I do if I miss a dose or vomit after taking TB medicine?
Do not take a double dose. Contact your TB team promptly so they can give you a clinician-directed plan, especially if vomiting or missed doses continue.
Which side effects from genitourinary TB medicines need urgent attention?
Contact the TB team urgently for new vision changes, yellow skin or eyes, dark urine, severe or persistent nausea or vomiting, abdominal pain, marked loss of appetite, unusual bleeding, rash, fever, or severe weakness. Do not decide on your own whether to stop or continue the medicines; follow the plan given by your clinicians.
Can rifampin affect birth control or my other medicines?
Yes. Rifampin can make many hormonal contraceptives less effective and can interact with blood thinners, HIV medicines, transplant medicines, methadone, seizure medicines, and other medicines. Give your TB team a complete medication list so they can recommend appropriate protection or adjustments.
Why do I need liver, kidney, and vision monitoring during treatment?
Baseline and risk-based monitoring helps detect medicine toxicity early and guide safe treatment. Liver tests are important because isoniazid, rifampin, and pyrazinamide can injure the liver, vision checks are important with ethambutol, and urologic follow-up helps watch for blockages or kidney damage from scarring.
Is orange urine normal during genitourinary TB treatment?
Rifampin can harmlessly turn urine, sweat, and tears orange. Tell your TB team about other concerning changes, such as yellow skin or eyes, dark urine, severe vomiting, or abdominal pain, because these may signal a serious problem.

Get notified when new evidence is published on Primary genito-urinary tuberculosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB).

    Mlyuka HJ, Liyoyo A, Nyaulingo B, et al.

    Trials 2026; (27(1)).

    PMID: 41612490
  2. 2

    Medical treatment for urogenital tuberculosis (UGTB).

    Wejse C

    GMS infectious diseases 2018; (6()):Doc04 doi:10.3205/id000039.

    PMID: 30671335
  3. 3

    Evaluation of Renal Functions in Patients with Genitourinary System Tuberculosis Involving the Kidney/Ureter: Single Center Experience.

    Sonmez G, Arslantas YB, Tosun H, et al.

    Journal of clinical practice and research 2024; (46(5)):470-474 doi:10.14744/cpr.2024.53792.

    PMID: 41256814
  4. 4

    Chronic kidney disease with genitourinary tuberculosis: old disease but ongoing complication.

    Kim EJ, Lee W, Jeong WY, et al.

    BMC nephrology 2018; (19(1)):193 doi:10.1186/s12882-018-0994-2.

    PMID: 30071831
  5. 5

    Genitourinary Tuberculosis: A Brief Manual for Urologists on Diagnosis and Treatment from the European Association of Urology Urological Infections Panel.

    Bausch K, Mantica G, Smith EJ, et al.

    European urology focus 2024; (10(1)):77-79 doi:10.1016/j.euf.2023.07.006.

    PMID: 37541917
  6. 6

    Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

    Nahid P, Dorman SE, Alipanah N, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (63(7)):e147-e195 doi:10.1093/cid/ciw376.

    PMID: 27516382
  7. 7

    Treatment of drug-susceptible tuberculosis among people living with human immunodeficiency virus infection: an update.

    Pettit AC, Shepherd BE, Sterling TR

    Current opinion in HIV and AIDS 2018; (13(6)):469-477 doi:10.1097/COH.0000000000000506.

    PMID: 30222609
  8. 8

    Effect of Digital Medication Event Reminder and Monitor-Observed Therapy vs Standard Directly Observed Therapy on Health-Related Quality of Life and Catastrophic Costs in Patients With Tuberculosis: A Secondary Analysis of a Randomized Clinical Trial.

    Manyazewal T, Woldeamanuel Y, Fekadu A, et al.

    JAMA network open 2022; (5(9)):e2230509 doi:10.1001/jamanetworkopen.2022.30509.

    PMID: 36107429
  9. 9

    Common Adverse Reactions and Management Strategies of First-Line Anti-Tuberculosis Drugs.

    He K, Zhang J, Du X, et al.

    Infection and drug resistance 2026; (19()):564580 doi:10.2147/IDR.S564580.

    PMID: 41939271
  10. 10

    Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis.

    Panjasawatwong N, Wattanakul T, Hoglund RM, et al.

    Antimicrobial agents and chemotherapy 2020; (65(1)) doi:10.1128/AAC.00487-20.

    PMID: 33139294
  11. 11

    High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

    Boeree MJ, Heinrich N, Aarnoutse R, et al.

    The Lancet. Infectious diseases 2017; (17(1)):39-49 doi:10.1016/S1473-3099(16)30274-2.

    PMID: 28100438
  12. 12

    Effect of Antituberculous Drugs on Serum Uric Acid and Urine Uric Acid Excretion.

    Louthrenoo W, Hongsongkiat S, Kasitanon N, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2015; (21(7)):346-8 doi:10.1097/RHU.0000000000000297.

    PMID: 26398460
  13. 13

    A pilot study to determine the occurrence of concomitant diseases and drug intake in patients on antituberculosis therapy.

    Jhaj R, Sharma S, Sabir M, Kokane A

    Journal of family medicine and primary care 2018; (7(2)):414-419 doi:10.4103/jfmpc.jfmpc_103_17.

    PMID: 30090786
  14. 14

    Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.

    Ford SL, Sutton K, Lou Y, et al.

    Antimicrobial agents and chemotherapy 2017; (61(10)) doi:10.1128/AAC.00487-17.

    PMID: 28739783
  15. 15

    Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps.

    Naidoo A, Naidoo K, Padayatchi N, Dooley KE

    The lancet. HIV 2022; (9(2)):e130-e138 doi:10.1016/S2352-3018(21)00324-6.

    PMID: 35120633
  16. 16

    Cutaneous Tuberculosis in Heart Transplant.

    Lino R, Amorim S, Silva C, et al.

    Transplantation proceedings 2023; (55(6)):1444-1448 doi:10.1016/j.transproceed.2023.03.041.

    PMID: 37142508
  17. 17

    Surgical Management of Genitourinary Tuberculosis: our Experience and review of literature.

    Mittal A, Ranjan S, Narain T, Panwar V

    Polski przeglad chirurgiczny 2020; (92(6)):1-6 doi:10.5604/01.3001.0014.3669.

    PMID: 33408264
  18. 18

    Genital tuberculosis: current status of diagnosis and management.

    Yadav S, Singh P, Hemal A, Kumar R

    Translational andrology and urology 2017; (6(2)):222-233 doi:10.21037/tau.2016.12.04.

    PMID: 28540230

This page is for informational purposes only and does not replace medical advice about genitourinary TB treatment. Your TB team and urologist should tailor your regimen and guide you about missed doses, interactions, and side effects.

Guide contents Primary genito-urinary tuberculosis
Research & Literature
04 Understanding Pathology and Lab Reports in Genitourinary TB 06 Surgical Interventions and Managing Complications